ONKURE THERAPEUTICS, INC. Cash and Restricted Cash
ONKURE THERAPEUTICS, INC. (OKUR) had Cash and Restricted Cash of $166.50 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $166.50M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $192.11M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $59.05M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70.33M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $166.50M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $192.11M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $59.05M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $70.33M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $83.37M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $96.66M 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $110.76M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $7.96M 10-Q · filed 2025-11-06 | $60.69M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $18.63M 10-Q · filed 2025-08-12 | $35.97M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $19.25M 10-Q · filed 2025-05-06 | $20.38M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $29.88M 10-K · filed 2026-03-12 | $27.63M 10-K · filed 2024-03-28 |
| 2023-09-30 | $11.74M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $9.08M 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $30.39M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $11.54M 10-K · filed 2025-03-10 | $19.93M 10-K · filed 2023-03-27 |
| 2022-09-30 | $62.13M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $118.26M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $121.09M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $124.66M 10-K · filed 2024-03-28 | |
| 2021-09-30 | $126.41M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $140.37M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $91.22M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $53.61M 10-K · filed 2023-03-27 | |
| 2020-09-30 | $11.85M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $16.34M 10-Q · filed 2021-08-11 | |
| 2020-03-31 | $18.28M 10-Q · filed 2021-05-20 | |
| 2019-12-31 | $17.50M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |